Novartis labeling changes
This article was originally published in The Tan Sheet
Executive Summary
Labeling of firm's Transderm Scop Rx motion sickness patch modified to remove statement claiming superiority over Pharmacia's OTC remedy Dramamine (oral dimenhydrinate), according to FDA's May 10 letter responding to Pharmacia petition. Agency determined comparative statement "is not supported by any data in Novartis' [NDA] for Transderm Scop," and requested it be removed from labeling. Novartis complied in a labeling supplement approved March 22. Novartis also removed superiority claim from DTC print ads, Web site after National Advertising Division determined evidence was insufficient to support the statement (1"The Tan Sheet" Nov. 13, 2000, p. 11)...
You may also be interested in...
Novartis Transderm Scop Comparative Claims With Dramamine Denied By NAD
DTC ad claims for Novartis' Rx Transderm Scop declaring superiority to Pharmacia's OTC motion sickness remedy Dramamine are inappropriate due to "very significant differences" between the scopolamine patch's consumer-targeted claims and original FDA-reviewed statements, NAD states Nov. 8.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.